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Summary
Background:  Bloodstream  infections  (BSIs)  caused  by  Gram-negative  (GN)  bacte-
ria  cause  signiﬁcant  morbidity  and  mortality.  There  is  a  worldwide  increase  in  the
reported  incidence  of  resistant  microorganisms;  therefore,  surveillance  programs
are  important  to  deﬁne  resistance  patterns  of  GN  microorganisms  causing  BSIs.  The
objective  of  this  study  was  to  describe  the  clinical  and  microbiological  features  of
resistant  GN  BSIs  in  a  tertiary  pediatric  hospital  in  Turkey.
Methods:  Patients  between  1  month  and  18  years  of  age  hospitalized  between
January  2005  and  December  2012  were  included  in  this  study.  The  presence  of
ESBL  and  AmpC  type  beta-lactamase  activity  were  evaluated  using  the  Clinical  and
Laboratory  Standards  Institute  (CLSI)  disk  diffusion  and  double-disk  synergy  tests.
Results:  A  total  of  209  resistant  GN  bacterial  BSI  episodes  were  identiﬁed  in  192
patients.  Of  192  children,  133  (69.2%)  were  aged  ≤48  months  of  age.  Sixty-six  (31.6%)
of  the  BSIs  were  considered  community-acquired  and  143  (68.4%)  were  hospital-
acquired  infections.  The  most  common  isolates  were  non-fermenting  GN  bacteria
(n  =  117,  55.9%).  The  major  causative  pathogens  were  Pseudomonas  spp.  in  non-
fermenting  GN  bacteria.  The  resistance  rates  to  imipenem  for  Pseudomonas  spp.  and
Acinetobacter  spp.  were  40.5%  and  41.6%,  respectively.  The  most  common  isolates
in  fatal  patients  were  Pseudomonas  spp.  followed  by  Escherichia  coli. The  overallPlease  cite  this  article  in  press  as:  Aydın  Teke  T,  et  al.  Clinical  and  microbiological  features  of  resistant  gram-negative
bloodstream  infections  in  children.  J  Infect  Public  Health  (2016),  http://dx.doi.org/10.1016/j.jiph.2016.04.011
28-day  mortality  rate  was  16.3%.
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Conclusions:  Although  our  study  was  performed  at  a single  center  and  represents  a
local  population,  based  on  this  study,  it  is  concluded  that  surveillance  programs  and
studies  of  novel  antibiotics  for  resistant  GN  bacteria  focusing  on  pediatric  patients
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
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for cultures  that  did  not  grow  for  10  days.  Con-
ﬁrmation of  bacterial  identiﬁcation  was  achieved
using conventional  methods,  such  as  a  Gram  stainare  required.
© 2016  King  Saud  Bin  Ab
Limited.  All  rights  reserv
Introduction
Bloodstream  infection  (BSI)  is a  clinical  syndrome
deﬁned as  the  presence  of  bacteria  in  the  blood,
and it  is  associated  with  high  morbidity  and  mor-
tality.  The  epidemiology  of  microbial  pathogens
causing BSI  has  changed  over  the  years,  with  an
increase  in  the  incidence  of  Gram-negative  (GN)
organisms  [1,2].  Prompt  and  appropriate  empirical
treatment  plays  a  critical  role  in  GN  BSIs.  How-
ever, the  increasing  prevalence  of  resistant  GN
bacteria  makes  the  empirical  treatment  of  BSIs
more difﬁcult  [3,4]. Although  the  use  of  antibiotics
and, therefore,  infections  due  to  resistant  orga-
nisms are  highly  common  in  hospital  settings,  and
antibiotic  resistance  has  recently  emerged  as  an
important  cause  of  community-acquired  BSIs  [5,6].
This increase  has  also  reduced  the  number  of  appro-
priate antibiotics  available  for  the  treatment  of
serious life-threatening  GN  BSIs.  By  contrast,  it  is
worrisome  that  this  increase  has  progressed  much
faster than  the  development  of  new  antibiotics.
Moreover, antibiotics  that  were  developed  and
those currently  under  development  are  generally
focused on  adults.  Studies  investigating  the  clini-
cal and  epidemiological  features  of  pediatric  BSIs
are lacking,  and  most  of  these  studies  are  focused
on speciﬁc  age  groups,  particular  microorganisms,
or underlying  diseases  [7—9].  The  objective  of  this
study is to  describe  the  clinical  and  microbiological
features of  community-  and  hospital-acquired  BSIs
and to  investigate  their  causative  pathogens  and
antibiotic  resistance  proﬁles,  as  well  as  mortality
caused by  BSIs,  in  a  tertiary  pediatric  hospital  in
Turkey.
Methods
This  retrospective  study  included  clinical  records
of hospitalized  patients  aged  between  1  monthPlease  cite  this  article  in  press  as:  Aydın  Teke  T,  et  al.  Clinical
bloodstream  infections  in  children.  J  Infect  Public  Health  (2
and 18  years  who  had  blood  culture  positivity
for resistant  GN  bacteria  at  Dr.  Sami  Ulus  Mater-
nity and  Children’s  Training  and  Research  Hospital
t
i
(etween  January  2005  and  December  2012.  Neona-
al patients,  outpatients,  patients  with  a hospital
tay shorter  than  24  h  and  patients  who  were
eferred to  our  hospital  from  other  health-care
acilities were  excluded  from  the  study.  Age,
ender, department  of  hospitalization,  underlying
iseases, history  of  hospitalization  within  the  last  3
r 6  months,  history  of  parenteral  or  oral  antibiotic
se, and  30-day  history  of  corticosteroid  or  other
mmunosuppressive  or  anticarcinogenic  drug  use,
urgical operations,  administration  of  hemodial-
sis, peritoneal  dialysis,  or  plasmapheresis,  and
se of  a mechanic  ventilator  and  central  venous
atheter were  recorded.  In  addition,  the  peripheral
eukocyte count,  erythrocyte  sedimentation  rate
ESR), and  C-reactive  protein  (CRP)  levels  that  were
ssessed on  the  day  when  the  positive  blood  cul-
ure was  obtained  were  recorded.  BSI  was  deﬁned
s the  isolation  of  a pathogen  microorganism
rom >1  blood  culture  bottle.  BSIs  were  classi-
ed as  community-  and  hospital-acquired  infections
nd were  compared  accordingly.  Pathogens  were
eﬁned  as  community-acquired  BSIs  if  detected
ithin the  ﬁrst  48  h  of  hospitalization,  and  they
ere deﬁned  as  hospital-acquired  BSIs  if  detected
fter  48  h  of  hospitalization.  The  recovery  of  differ-
nt species  72  h  after  the  previous  positive  blood
ulture  in  a  single  patient  was  considered  to  be
 distinct  episode.  Isolation  of  the  same  microor-
anism from  a  single  patient  was  considered  to  be
 single  episode  even  if  the  culture  was  obtained
fter 72  h.
The  blood  cultures  were  incubated  in  a
acT/Alert automated  culture  system  at  37 ◦C  for
4—48 h  (bioMérieux®, France)  and  then  Gram-
tained and  subcultured  onto  plates  containing  5%
heep blood  agar,  eosin  methylene  blue  agar,  and
hocolate  agar.  A  control  passage  was  performed and  microbiological  features  of  resistant  gram-negative
016),  http://dx.doi.org/10.1016/j.jiph.2016.04.011
est, oxidase  test,  lactose  fermentation,  urea  test,
ndole test,  and  motility  test,  with  an  API  20E
bioMérieux®, France)  in  fermenting  GN  bacteria
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Table  1  Underlying  diseases  of  the  patients  with
gram-negative  bacteremia.
n  %
Underlying  disease  162  77.5
Neurological  disease  30  14.4
Cardiac  disease  23  11
Solid  tumor  23  11
Gastrointestinal  system  disease  21  10
Hematologic  disease  14  6.7
Nephrologic  and  rheumatologic
disease
12 5.7
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ram-negative  bloodstream  infections  
nd  an  API  20NE  (bioMérieux®, France)  in  non-
ermenting GN  bacteria  between  2004  and  2009.
owever, by  using  this  method,  some  of  the  non-
ermenting  GN  bacteria  could  not  be  identiﬁed  at
he species  level.  The  tests  were  performed  with
 PhoenixTM-100  (BD,  Diagnostic  Instrument  Sys-
em, Sparks,  USA)  between  2009  and  2011  and  with
 VITEK  2  ID-AST  (bioMérieux,  France)  automated
ystem after  2011.  The  antibiotic  susceptibility  of
lood isolates  was  assessed  using  an  automated
ystem as  well  as  the  Kirby-Bauer  Disk  Diffusion
ethod and  an  extended-spectrum  beta-lactamase
ESBL) assay.  The  AmpC  beta-lactamase  activity  was
etected using  double-disk  synergy  and  disk  diffu-
ion methods  according  to  the  Clinical  Laboratory
tandard Institute  (CLSI)  guidelines.
tatistical analysis
ata  were  analyzed  using  SPSS  15.0.  Categorical
ariables were  evaluated  by  the  chi-square  test,
nd continuous  variables  were  evaluated  by  the
ann—Whitney  U  test  and  t-test.  A  p  value  of  <0.05
as considered  signiﬁcant.
esults
hroughout  the  study,  a  total  of  209  resistant
N BSI  episodes  were  identiﬁed  in  192  patients.
he patients  comprised  112  (58.3%)  males  and  80
41.7%) females,  with  a  mean  age  of  42.5  ±  52.6
onths  (median,  15;  range,  1—204  months).  The
atients  were  classiﬁed  into  three  age  groups
s follows:  1—12  months  (n  =  83,  43.2%),  13—48
onths (n  =  50,  26%),  and  49—216  months  (n  =  59,
0.7%).  Most  of  the  patients  were  hospitalized  in
he general  pediatrics  department  (n  =  168,  80.4%),
ollowed  by  pediatric  surgery  (n  =  22,  10.5%)  and
he pediatric  intensive  care  unit  (n  =  19,  9.1%).
nderlying diseases  were  present  in  162  (84.4%)
atients, and  the  most  common  underlying  disease
as neurological  disease  (n  =  30;  14%),  followed  by
ongenital  or  acquired  heart  disease  (n  =  23,  12%)
nd solid  tumor  (n  =  23,  12%).  The  hospitalization
ate and  history  of  antibiotic  use  within  the  last
 months  were  65.6%  (n  =  137)  and  75.6%  (n  =  158),
espectively,  and  the  hospitalization  rate  and  his-
ory of  antibiotic  use  within  the  last  6 months
ere 70.8%  (n  =  148)  and  78.5%  (n  = 164),  respec-Please  cite  this  article  in  press  as:  Aydın  Teke  T,  et  al.  Clinical
bloodstream  infections  in  children.  J  Infect  Public  Health  (2
ively. Within  the  30  days  before  the  diagnosis  of
N BSI,  34 (16.3%)  patients  underwent  chemother-
py administration,  19  (9.1%)  underwent  surgery,  6
2.9%) used  corticosteroid,  and  6  (2.9%)  underwent
b
P
a
wRespiratory  tract  disease 11  5.3
Others  28  13.4
emodialysis  or  peritoneal  dialysis.  At  the  time  of
iagnosis, twenty-six  (12.4%)  patients  were  being
ollowed-up  by  mechanical  ventilation,  and  a cen-
ral venous  catheter  was  present  in  24  (11.5%)
atients. The  results  are  presented  in  Table  1.
he mean  hospital  stay  following  the  diagnosis  of
N BSI  was  22.6  ±  32.4  days  (median,  14;  range,
—240 days).
The resistant  GN  BSIs  comprised  66  (31.6%)
ommunity- and  143  (68.4%)  hospital-acquired
nfections.  The  CRP  level  was  higher  in  hospital-
cquired infections  (p  = 0.000).  The  presence  of
nderlying  diseases,  antibiotic  use,  chemother-
py administration,  presence  of  a central  venous
atheter,  and  ongoing  ventilation  treatment  were
ore common  in  hospital-acquired  infections.  The
verall 28-day  mortality  was  higher  in  hospital-
cquired infections  (Table  2). Non-fermenting  GN
acilli accounted  for  117  (55.9%)  of  the  causative
gents. Table  3  presents  the  distribution  of  microor-
anisms  detected  for  community-  and  hospital-
cquired BSIs.  Non-fermenting  species,  except
or Pseudomonas  and  Acinetobacter,  were  more
ommon  in  community-acquired  BSIs  (p  = 0.01),
hereas  Klebsiella  spp.  were  more  common  in
ospital-acquired  BSIs  (p  =  0.035).  Underlying  dis-
ases were  present  in  57.8%  (11/19)  of  the  patients
ith community-acquired  BSIs  caused  by  Pseu-
omonas  spp.  and  in  66.6%  (18/27)  of  the  patients
ith community-acquired  BSIs  caused  by  non-
ermenting  GN  bacilli  other  than  Pseudomonas
nd Acinetobacter  spp.  One  patient  had  cystic
brosis  associated  with  a BSI  caused  by  Acine-
obacter baumannii. This  isolate  was  susceptible
o carbapenem.  In hospital-acquired  isolates,  the
esistance  of  Acinetobacter  spp.  to  imipenem  was
1.6%, and  all  Acinetobacter  spp.  were  suscepti- and  microbiological  features  of  resistant  gram-negative
016),  http://dx.doi.org/10.1016/j.jiph.2016.04.011
le to  colistin.  In  community-  and  hospital-acquired
seudomonas  spp.,  imipenem  resistance  was  15.7%
nd 53%,  respectively,  and  half  of  the  isolates
ere susceptible  to  colistin.  In  non-fermenting  GN
ARTICLE INJIPH-577; No. of Pages 8
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Table  2  The  distribution  of  the  gram-negative
microorganisms  responsible  from  bacteremia.
Microorganism  Total  (n  =  209)
n  %
Non-fermenting  bacillia 55  26.3
Brevundimonas  vesicularis 6
Flavimonas  oryzihabitans 5
Burkholderia  cepacia 4
Burkholderia  gladioli  3
Sphingomonas  paucimobilis  3
Raltsonia  picketii  2
Cryseomonas  luteola  2
Elizabethkingia  meningoseptica  2
Stenotrophomonas  maltophilia  1
Pastorella  pneumotropica  1
Shewanella  putrefaciens  1
Alcaligenes  xylosoxidans  1
Cupriavidus  pauculus  1
Comomonas  testosteroni  1
Achromobacter  denitriﬁcans  1
Pseudomonas  spp.  49  23.4
P.  aeroginosa  23
K.  pneumonia  32  15.3
Enterobacter  spp.  30  14.4
E.  cloaca  19
E.  coli  25  12
Acinetobacter  baumannii  complex  13  6.2
Serratia  marcescens  3  1.5
C.  freundii  2  1
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domonas and Acinetobacter spp.
bacilli  other  than  Pseudomonas  and  Acinetobac-
ter spp.,  imipenem  resistance  was  remarkably  low
(0% and  3.5%,  respectively),  colistin  resistance  wasPlease  cite  this  article  in  press  as:  Aydın  Teke  T,  et  al.  Clinical
bloodstream  infections  in  children.  J  Infect  Public  Health  (2
considerably  high  (85%  and  85.7%,  respectively),
and ciproﬂoxacin  resistance  was  low  (7.6%  and
10.7%,  respectively).  In  Klebsiella  spp.,  imipenem
Table  3  The  gram-negative  microorganisms  isolated
from  fatal  patients.
Pathogen  Mortality
n  %
Pseudomonas  spp.  13  38.2
E.  coli  6  17.6
Non-fermentinga bacilli  4  11.7
Enterobacter  spp.  4  11.7
Klebsiella  spp.  3  8.8
Acinetobacter  spp.  3  8.8
Serratia  spp.  1  2.9
C.  freundii  0  0
Total  34
a Non-fermenting gram-negative bacilli excluding Pseu-
domonas and Acinetobacter spp.
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esistance  was  0%  and  3.7%  and  ciproﬂoxacin  resis-
ance was  20%  and  14.5%,  respectively.  No  colistin
esistance  was  detected.  More  than  half  of  the
ospital-acquired Klebsiella  spp.  (66.6%)  was  resis-
ant to  gentamicin.  In  community-  and  hospital-
cquired Enterobacter  spp.,  imipenem  resistance
as 0%  and  31.8%  and  ciproﬂoxacin  resistance  was
% and  4.5%,  respectively.  No  colistin  resistance
as detected.  Additionally  in  these  species,  amino-
lycoside  resistance  was  low.  In Escherichia  coli
solates,  imipenem  resistance  was  low,  whereas
alf of  the  hospital-acquired  isolates  were  resis-
ant to  ciproﬂoxacin  and  no  colistin  resistance  was
etected.  In  these  species,  gentamicin  resistance
as remarkably  high  (100%  and  60%,  respectively).
erratia and  Citrobacter  spp.  showed  no  resis-
ance to  imipenem,  ciproﬂoxacin,  and  colistin.
able  3 presents  the  resistance  proﬁles  of  ESBL-
nd AmpC  beta-lactamase-producing  microorgan-
sms to  aztreonam,  imipenem,  ciproﬂoxacin,
rimethoprim-sulfamethoxazole  (TMP-SMX),  col-
stin, gentamicin,  and  amikacin.
The overall  28-day  mortality  was  16.3%  (n  =  34).
n these  patients,  the  most  commonly  isolated
trains were  Pseudomonas  spp.  followed  by  E.  coli
pp.
iscussion
n  this  study,  the  clinical  and  microbiological  fea-
ures of  BSIs  caused  by  resistant  GN  bacteria  in
ediatric  patients  and  their  resistance  proﬁles  were
valuated.  The  BSIs  caused  by  GN  bacteria  were
ore  common  in  the  youngest  age  group.  A  study
ased  on  hospital  discharge  data  obtained  from
arious hospitals  in  7 states  of  the  USA  reported
hat the  annual  age-  and  gender-adjusted  inci-
ence of  sepsis  was  0.56/1000  in  all  pediatric  cases,
nd the  highest  age-adjusted  incidence  was  in
nfants (5.16/1000),  which  decreased  to  0.20/1000
n patients  aged  10—14  years  [10]. In  a population-
ased study,  56  children  were  identiﬁed  with  GN
SI, and  the  annual  gender-adjusted  incidence  rate
f GN  BSI  per  100,000  persons  was  129.7  in  infants;
his rated  signiﬁcantly  decreased  to  14.6  and  7.6
n children  aged  1—4  and  5—18  years,  respectively
7].
Pediatric  studies  on  community-  and  hospital-
cquired BSIs  reported  various  rates  of  underlying
iseases, which  vary  according  to  the  population and  microbiological  features  of  resistant  gram-negative
016),  http://dx.doi.org/10.1016/j.jiph.2016.04.011
f the  health-care  facility.  Common  underlying
iseases include  preterm  delivery,  malnutrition,
ydrocephaly, meningomyelocele,  convulsive  dis-
ases, neutropenia,  organ  transplantation,  use  of
 INJIPH-577; No. of Pages 8
G
s
l
b
m
w
o
n
h
v
a
t
f
G
B
d
c
a
p
s
a
w
p
l
a
m
o
[
o
t
r
p
s
i
f
o
[
b
p
t
o
o
I
(
t
i
r
m
(
[
a
T
t
b
p
A
t
w
i
h
i
w
b
i
o
[
s
p
c
i
s
I
(
b
c
c
p
e
b
i
i
i
t
b
t
l
A
i
c
r
p
a
K
i
m
E
m
p
w
e
[
t
g
iARTICLE
ram-negative  bloodstream  infections  
teroids  or  other  immunosuppressive  drugs,  cancer,
iver failure,  congenital  heart  disease,  neurogenic
ladder, chronic  kidney  disease,  cystic  ﬁbrosis,  and
alaria [7,11—14].  In  our  study,  underlying  diseases
ere present  in  approximately  three-quarters  of
ur patients,  and  the  most  common  diseases  were
euromuscular.
The role  of  GN  bacteria  in  community-  and
ospital-acquired  BSIs  has  been  reported  with
arying rates  [4,15,16]. In  our  study,  hospital-
cquired infections  accounted  for  approximately
hree-quarters  of  the  resistant  GN  BSIs.
AmpC  beta-lactamase-producing  non-
ermenting bacilli  were  the  most  common  resistant
N bacteria  in  community-  and  hospital-acquired
SIs. A  retrospective  study  investigated  the  epi-
emiological  and  clinical  outcomes  of  bacteremia
aused by  multidrug-resistant  Enterobacteriaceae
nd non-fermenting  bacilli  in  a  European  tertiary
ediatric hospital  during  a  12-month  period.  The
tudy identiﬁed  136  blood  cultures  in  119  patients
nd  reported  that  86.3%  of  the  patients  presented
ith an  underlying  disease.  The  median  age  of  the
atients  was  1.1  years;  the  most  commonly  iso-
ated strains  were  Klebsiella  pneumoniae, E.  coli
nd Pseudomonas  aeruginosa; the  percentage  of
ultidrug-resistant  organisms  was  39%;  and  67.6%
f the  infections  were  acquired  in  hospital  settings
17].
Non-fermenting  GN  bacilli  are  important  agents
f infections  acquired  in  hospital  settings,  par-
icularly  in  intensive  care  units.  However,  recent
eports demonstrated  that  these  pathogens  also
lay a  role  in  community-acquired  infections.  In  a
tudy on  the  clinical  impact  of  GN  non-fermenters
n adults  with  community-onset  bacteremia,  non-
ermenting  GN  bacilli  were  detected  in  31  (6%)
f 565  adults  with  community-acquired  bacteremia
6].  In our  study,  these  agents  were  responsi-
le for  over  half  of  the  BSIs  detected  in  our
atients. In  a  population-based  study  that  inves-
igated  the  BSIs  caused  by  GN  bacilli  in  children
ver a  10-year  period,  P.  aeruginosa  was  the  sec-
nd most  common  pathogen  after  E.  coli  [7].
n the  SENTRY  Antimicrobial  Surveillance  Program
1997—2002),  the  prevalence  of  P.  aeruginosa  was
wo-fold  higher  in  hospital-acquired  infections  than
n community-acquired  infections  and  multidrug
esistant P.  aeruginosa  was  relatively  more  com-
on in  hospital  settings  and  intensive  care  units
community-acquired,  3.4%;  hospital-acquired,  9%)
18].  In  our  study,  Pseudomonas  spp.  were  detectedPlease  cite  this  article  in  press  as:  Aydın  Teke  T,  et  al.  Clinical
bloodstream  infections  in  children.  J  Infect  Public  Health  (2
t high  rates  in  community-acquired  infections.
his is  attributed  to  underlying  diseases  leading
o secondary  immunosuppression,  such  as  dia-
etes mellitus  and  chronic  kidney  disease,  or
p
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rimary  immunodeﬁciency  diseases.  In  the  SENTRY
ntimicrobial  Surveillance  Program  (1997—2007),
he resistance  of  P.  aeruginosa  to  imipenem
as 20%  [19]. In  our  study,  the  prevalence  of
mipenem-resistant  Pseudomonas  was  considerably
igh (40.5%).  In  the  Meropenem  Yearly  Susceptibil-
ty Test  Information  Collection  (MYSTIC)  program,
hich  investigates  the  in  vitro  susceptibility  of
acterial isolates  to  meropenem  worldwide,  the
ntensive care  units  in  Turkey  had  the  highest  rate
f multidrug  resistant  P.  aeruginosa  spp.  (50%)
20]. In  our  study,  the  resistance  of  Pseudomonas
pp. to  carbapenem  was  remarkably  high  com-
ared to  the  lower  resistance  to  aminoglycoside  and
iproﬂoxacin.
A. baumannii  has  recently  emerged  as  an
mportant agent  of  infections  acquired  in  hospital
ettings,  particularly  in  intensive  care  units  [21].
n the  SENTRY  Antimicrobial  Surveillance  Program
1997—2002), Acinetobacter  spp.  were  responsi-
le for  2.9%  of  hospital-acquired  BSIs  and  1.2%  of
ommunity-acquired  BSIs  [18].  In  our  study,  BSI
aused by  A.  baumannii  was  present  in  only  one
atient  who  had  cystic  ﬁbrosis.  Although  carbapen-
ms are  the  ﬁrst-line  treatment  for  BSIs  caused
y Acinetobacter  spp.,  colistin  has  also  become  an
mportant treatment  option  worldwide  due  to  the
ncreasing  resistance  to  carbapenem.  The  rate  of
mipenem-resistant  A.  baumannii  spp.  in  patients
reated  in  intensive  care  units  increased  ﬁve-fold
etween 2001  and  2008  [22].  In  the  2011  report  by
he Turkish  National  Nosocomial  Infections  Surveil-
ance Network,  the  resistance  to  carbapenem  for
. baumannii  spp.  isolated  from  hospital-acquired
nfections  was  74%  [23]. In  our  study,  resistance  to
arbapenem  was  higher  than  40%  and  no  colistin
esistance was  detected.
Klebsiella  spp.  is  the  second  most  common
athogens of  both  community-  and  hospital-
cquired GN  BSIs  after  E.  coli  [16,24]. In  our  study,
lebsiella  spp.  was  the  most  common  pathogens
n hospital-acquired  BSIs.  K.  pneumoniae  is  the
ost frequent  ESBL-producing  organism  of  the
nterobactericea  [21,25]. Carbapenems  are  the
ost effective  agents  for  the  treatment  of  ESBL-
roducing K.  pneumoniae  infections.  However,  the
idespread  use  of  carbapenems  has  led  to  the
mergence of  carbapenemase-producing  strains
26]. In  our  study,  the  resistance  of  Klebsiella  spp.
o imipenem  was  4.3%.  In  a study  that  investi-
ated BSIs  caused  by  ESBL-producing  Klebsiella  spp.
n children  in  Turkey  over  a 4-year  period,  the and  microbiological  features  of  resistant  gram-negative
016),  http://dx.doi.org/10.1016/j.jiph.2016.04.011
revalence of  ESBL-producing  isolates  was  57.1%
nd carbapenem  resistance  was  0%  [27]. Studies
howed  that  the  frequent  use  of  quinolones,  par-
icularly  for  the  treatment  of  GN  bacilli  infections
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in  adults,  results  in  a  number  of  mechanisms  that
lead to  resistance  to  quinolones  and  the  emergence
of plasmid-mediated  resistance  in  ESBL-producing
Klebsiella spp.  [28]. In  this  study,  the  resistance  of
Klebsiella spp.  to  ciproﬂoxacin  was  16.6%,  which
was lower  than  the  rates  reported  in  other  adult
studies. We  propose  that  this  outcome  is  attributed
to the  limited  use  of  quinolones  in  children  com-
pared to  adults  and  therefore  is  the  reason  for  the
low-level  of  quinolone  resistance.
E. coli  is  the  most  frequently  isolated  GN  bacilli
both in  community-  and  hospital-acquired  BSIs
[4,29].  In  our  study,  E.  coli  was  the  ﬁfth  most
common pathogen  in  all  infections,  and  it  was
more frequently  detected  in  hospital-acquired  BSIs
compared  to  community-acquired  BSIs.  Moreover,
ESBL production  was  detected  in  all  E.  coli  iso-
lates. ESBL-producing  E.  coli  isolates  are  generally
resistant to  ﬂuoroquinolones,  TMP-SMX,  and  amino-
glycosides.  A  study  identiﬁed  95  ESBL-producing  E.
coli isolates  and  reported  the  rates  of  resistance  to
ciproﬂoxacin,  TMP-SMX,  amikacin,  and  imipenem  as
36%, 37%,  85%,  and  100%,  respectively  [30]. In  our
study, the  rates  of  resistance  to  ciproﬂoxacin,  TMP-
SMX, and  amikacin  were  similar  to  these  previously
reported rates  (52%,  25%,  and  76%,  respectively),
whereas resistance  to  imipenem  was  signiﬁcantly
lower (5.2%).
In a  surveillance  study  by  the  Centers  for  Disease
Control and  Prevention  (CDC),  Enterobacter  was
reported  as  the  ﬁfth  most  common  pathogen  iso-
lated from  patients  treated  at  intensive  care  units
(5—8.6%)  [31].  In  our  study,  Enterobacter  spp.  were
the fourth  most  common  microorganisms  isolated
from  infections.  During  treatment,  Enterobacter
spp. is  likely  to  exhibit  rapid  resistance  to  third-
generation  cephalosporins  via  the  production  of
AmpC Beta-lactamase.  In  a  study  on  the  clinical
features of  BSIs  caused  by  Enterobacter  cloacae,
3.5%  of  the  isolates  were  ESBL-producers,  whereas
59.6%  and  31.6%  of  the  isolated  included  inducible
and  derepressed  AmpC  enzymes,  respectively,  and
all of  the  isolates  were  susceptible  to  imipenem,
meropenem, gentamicin,  and  ciproﬂoxacin  [32]. In
our study,  Enterobacter  spp.  were  most  susceptible
to aminoglycosides  and  ciproﬂoxacin.  Enterobacter
spp. become  resistant  to  carbapenems  by  producing
carbapenemase  [33].  In  a  study  on  the  molecu-
lar epidemiology  of  carbapenem  resistance  in  E.
cloacae strains,  3.55%  (35/986)  of  the  strains  were
carbapenem-resistant  isolates  [34].  In  our  study,
imipenem  resistance  in  E.  cloacae  strains  was  foundPlease  cite  this  article  in  press  as:  Aydın  Teke  T,  et  al.  Clinical
bloodstream  infections  in  children.  J  Infect  Public  Health  (2
in one-third  of  the  isolates.
Mortality  in  patients  with  BSI  may  be  asso-
ciated with  a  number  of  factors,  including  the
severity of  infection,  underlying  diseases,  age,  and PRESS
T.  Aydın  Teke  et  al.
nappropriate  empirical  antibiotic  therapy.  The
verall 28-day  mortality  reported  in  patients  with
N BSI  varies  between  11  and  26.2%  [4,7].  In  our
tudy, the  overall  28-day  mortality  was  16.3%.  In
hese patients,  Pseudomonas  spp.  was  the  most  fre-
uently isolated  pathogens.  Moreover,  BSIs  caused
y Pseudomonas  spp.  lead  to  high  mortality.  In
 study  previously  conducted  in  our  hospital  that
xcluded  patients  in  intensive  care  units,  the  mor-
ality rate  for  171  patients  was  27.5%,  and  similar
o our  study,  P.  aeruginosa  was  associated  with  high
ortality [35].
Our  study  has  several  limitations.  First,  the  sam-
le size  was  small  because  the  study  was  conducted
t a single  center.  Second,  most  of  the  patients  had
n underlying  disease  making  them  prone  to  infec-
ion. Finally,  neonatal  patients,  who  have  a  high
ate of  hospitalization,  were  excluded  from  this
tudy.
onclusion
tudies  of  pathogens  responsible  for  bloodstream
nfections and  their  antibiotic  resistance  pat-
erns are  critically  important  for  deﬁning  prompt
nd appropriate  treatments.  Antibiotic  resistance
urveillance  programs  and  studies  of  novel  antibi-
tics for  resistant  GN  bacteria  focusing  on  pediatric
atients are  required.
unding
o  funding  sources.
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